References

Publication Details

1.
National Institute for Health and Clinical Excellence. Guideline development methods: information for national collaborating centres and guideline developers. London: National Institute for Health and Clinical Excellence; 2004. Ref ID: 20114.
2.
Parkinson’s Disease Society. Parkinson’s disease: the personal view. London: Parkinson’s Disease Society; 1993. Ref ID: 19909.
3.
Dateline interview: Michael J Fox. New York: NBC News; 2003. Ref ID: 19911.
4.
Parkinson’s Disease SocietyOne in twenty: an information pack for younger people with Parkinson’s London: Parkinson’s Disease Society; 2002Ref ID: 19910.
5.
Parkinson J. Essay on the shaking palsy. London: Sherwood, Neely, and Jones; 1817. Ref ID: 19927.
6.
Burch B, Sheerin F. Parkinson’s disease. Lancet. 2005;365:622–627. Ref ID: 19928. [PubMed: 15708109]
7.
Goetz CG. Excerpts from nine case presentations on general neurology delivered at the Salpetriere Hospital in 1887–8. In: Charcot JM, editor. The Tuesday lessons. New York: Raven Press; 1987. Ref ID: 19929. [PubMed: 2670012]
8.
Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson’s disease. Movement Disorders. 1998;13(2):249–254. Ref ID: 19653. [PubMed: 9539337]
9.
Ben-Shlomo Y. The epidemiology of Parkinson’s disease. In: Quinn NP, editor. Parkinsonism. London: Bailliere-Tindall; 1997. pp. 55–68. Ref ID: 20125. [PubMed: 9426868]
10.
Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: A research survey in the United Kingdom. Movement Disorders. 2003;18(10):1139–1145. Ref ID: 40. [PubMed: 14534917]
11.
Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics. 2001;19(10):1013–1038. Ref ID: 19691. [PubMed: 11735671]
12.
Wood BH, Bilclough JA, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. Journal of Neurology, Neurosurgery & Psychiatry. 2002;72:721–725. Ref ID: 19857. [PMC free article: PMC1737913] [PubMed: 12023412]
13.
National Institute for Health and Clinical Excellence. Guideline development methods: an overview for stakeholders, the public and the NHS. London: National Institute for Health and Clinical Excellence; 2004. Ref ID: 20115.
14.
The national service framework for long-term (neurological) conditions. Department of Health. London: HMSO; 2005. Ref ID: 19904.
15.
Department of Health. The national service framework for older people. London: HMSO; 2001. Ref ID: 19942.
16.
National Institute for Health and Clinical Excellence. Falls: The assessment and prevention of falls in older people. (Clinical Guideline 21). London: National Institute for Health and Clinical Excellence; 2004. Ref ID: 19925. [PubMed: 25506960]
17.
National Institute for Health and Clinical Excellence and Social Care Institute for Excellence. Dementia: management of dementia, including use of antipsychotic medication in older people (In progress). London: National Institute for Health and Clinical Excellence; 2007. Ref ID: 19926.
18.
National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. (Clinical Guideline 23). London: National Institute for Clinical Excellence; 2004. Ref ID: 19852.
19.
National Institute for Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. (Clinical Guideline 20). London: National Institute for Clinical Excellence; 2004. Ref ID: 20031.
20.
National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer’s disease. (Technology Appraisal Guidance 19). London: National Institute for Clinical Excellence; 2001. Ref ID: 19943.
21.
National Institute for Clinical Excellence. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. (Clinical Guideline 22). London: National Institute for Clinical Excellence; 2004. Ref ID: 19941. [PubMed: 20945576]
22.
National Institute for Clinical and Public Health Excellence. Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition. (Clinical Guideline 32). London: National Institute for Clinical and Public Health Excellence; 2006. Ref ID: 20124. [PubMed: 31877003]
23.
National Institute for Clinical Excellence. Deep brain stimulation for Parkinson’s disease (IPG019). London: NICE; 2003. Ref ID: 95.
24.
National Collaborating Centre for Chronic Conditions. Methodology pack. London: NCC-CC; 2006. Available from: www​.rcplondon.ac.uk/college/NCC-CC. Ref ID: 20117.
25.
Department of Health. The expert patient: a new approach to chronic disease management for the 21st century. London: Department of Health; 2001. Ref ID: 19595.
26.
Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial. PROPATH Advisory Board. American Journal of Medicine. 1994;97(5):429–435. Ref ID: 737. [PubMed: 7977431]
27.
Mercer BS. A randomized study of the efficacy of the PROPATH program for patients with Parkinson disease. Archives of Neurology. 1996;53:881–884. Ref ID: 739. [PubMed: 8815853]
28.
Findley L, Eichhorn T, Janca A, et al. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Movement Disorders. 2002;17(1):60–67. Ref ID: 742. [PubMed: 11835440]
29.
Habermann B. Day-to-day demands of Parkinson’s disease. Western Journal of Nursing Research. 1996;18(4):397–413. Ref ID: 65. [PubMed: 8797365]
30.
Pentland B, Pitkairn TK, Gray TK. The effects of reduced expression in Parkinson’s disease in impression formation by health professionals. Clinical Rehabilitation. 1987;1:307–313. Ref ID: 2766.
31.
Yarrow S. Survey of members of the Parkinson’s Disease Society. London: Parkinson’s Disease Society of the United Kingdom and Policy Studies Institute; 1999. Ref ID: 786.
32.
Shimbo T, Goto M, Morimoto T, et al. Association between patient education and health-related quality of life in patients with Parkinson’s disease. Quality of Life Research. 2004;13(1):81–89. Ref ID: 19841. [PubMed: 15058790]
33.
Meadowcroft RS, Scott S, Woodford C. Communicating with people with Parkinson’s and their carers. London: Parkinson’s Disease Society; 2005. Ref ID: 19903.
34.
Bennett DA, Beckett AM, Shannon KM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New England Journal of Medicine. 1996;334(24):71–76. Ref ID: 2772. [PubMed: 8531961]
35.
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1988;51(6):745–752. Ref ID: 2773. [PMC free article: PMC1033142] [PubMed: 2841426]
36.
Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism - A prospective study. Canadian Journal of Neurological Sciences. 1991;18(3):275–278. Ref ID: 111. [PubMed: 1913360]
37.
Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery & Psychiatry. 1992;55(3):181–184. Ref ID: 99. [PMC free article: PMC1014720] [PubMed: 1564476]
38.
Hughes AJ, Daniel SE, Ben Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt:4):4–70. Ref ID: 96. [PubMed: 11912118]
39.
Schrag A, Ben Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(5):529–534. Ref ID: 142. [PMC free article: PMC1738115] [PubMed: 12397145]
40.
Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age & Ageing. 1999;28(2):99–102. Ref ID: 108. [PubMed: 10350403]
41.
Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson disease. Archives of Neurology. 2000;57(3):369–372. Ref ID: 81. [PubMed: 10714663]
42.
Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57(9):1687–1694. Ref ID: 2309. [PubMed: 11706112]
43.
Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Movement Disorders. 2003;18(9):977–984. Ref ID: 425. [PubMed: 14502664]
44.
Popperl G, Radau P, Linke R, et al. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nuclear Medicine Communications. 2005;26(1):39–43. Ref ID: 19822. [PubMed: 15604946]
45.
Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Movement Disorders. 2000;15(3):503–510. Ref ID: 484. [PubMed: 10830416]
46.
Booij J, Speelman JD, Horstink MW, et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. European Journal of Nuclear Medicine. 2001;28(3):266–272. Ref ID: 467. [PubMed: 11315592]
47.
Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. European Journal of Nuclear Medicine & Molecular Imaging. 2002;29(12):1623–1629. Ref ID: 439. [PubMed: 12458397]
48.
Prunier C, Tranquart F, Cottier JP, et al. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nuclear Medicine Communications. 2001;22(11):1207–1214. Ref ID: 459. [PubMed: 11606886]
49.
Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000;55(10):1540–1547. Ref ID: 475. [PubMed: 11094111]
50.
Van Laere K, De Ceuninck L, Dom R, et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP- beta-CIT versus 99mTc-TRODAT-1. European Journal of Nuclear Medicine & Molecular Imaging. 2004;31(8):1119–1127. Ref ID: 19824. [PubMed: 15064872]
51.
Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism & Related Disorders. 2004;10(6):375–379. Ref ID: 19817. [PubMed: 15261880]
52.
Asenbaum S, Pirker W, Angelberger P, et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. Journal of Neural Transmission. 1998;105:10–12. 1213–1228. Ref ID: 507. [PubMed: 9928890]
53.
Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson’s disease. European Journal of Nuclear Medicine. 1999;26(11):1413–1423. Ref ID: 196. [PubMed: 10552082]
54.
Varrone A, Marek KL, Jennings D, et al. [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Movement Disorders. 2001;16(6):1023–1032. Ref ID: 453. [PubMed: 11748733]
55.
Huang WS, Lee MS, Lin JC, et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson’s disease. European Journal of Nuclear Medicine & Molecular Imaging. 2004;31(2):155–161. Ref ID: 19820. [PubMed: 15129696]
56.
Catafau AM, Tolosa E, Laloux P, et al. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders. 2004;19(10):1175–1182. Ref ID: 19823. [PubMed: 15390019]
57.
Weng YH, Yen TC, Chen MC, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson’s disease from healthy subjects. Journal of Nuclear Medicine. 2004;45(3):393–401. Ref ID: 19821. [PubMed: 15001678]
58.
Jennings DL, Seibyl JP, Oakes D, et al. [123I]beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Archives of Neurology. 2004;61(8):1224–1229. Ref ID: 19818. [PubMed: 15313838]
59.
Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach. Movement Disorders. 2003;18(Suppl 7):S52–62. Ref ID: 19666. [PubMed: 14531047]
60.
Holloway R, Shoulson I, Kieburtz K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Journal of the American Medical Association. 2000;284(15):1931–1938. Ref ID: 1477. [PubMed: 11035889]
61.
Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology. 2003;54(1):93–101. Ref ID: 808. [PubMed: 12838524]
62.
Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. New England Journal of Medicine. 2004;351(24):2498–2508. Ref ID: 19725. [PubMed: 15590952]
63.
Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. Journal of Neurology, Neurosurgery & Psychiatry. 1994;57(3):278–284. Ref ID: 329. [PMC free article: PMC1072814] [PubMed: 8158173]
64.
Schocke MFH, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002;58(4):575–580. Ref ID: 130. [PubMed: 11865135]
65.
Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: A critical review and meta-analysis. Journal of the International Neuropsychological Society. 1997;3(2):179–194. Ref ID: 29. [PubMed: 9126859]
66.
Bhattacharya K, Saadia D, Eisenkraft B, et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: A diagnostic algorithm. Archives of Neurology. 2002;59(5):835–842. Ref ID: 13. [PubMed: 12020268]
67.
Juh R, Kim J, Moon D, et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. European Journal of Radiology. 2004;51(3):223–233. Ref ID: 19839. [PubMed: 15294329]
68.
Schreckenberger M, Hagele S, Siessmeier T, et al. The dopamine D2 receptor ligand 18F-desmethoxy-fallypride: An appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. European Journal of Nuclear Medicine & Molecular Imaging. 2004;31(8):1128–1135. Ref ID: 19838. [PubMed: 15042325]
69.
Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson’s disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995;45(11):1995–2004. Ref ID: 291. [PubMed: 7501148]
70.
Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson’s disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Archives of Neurology. 1994;51(3):237–243. Ref ID: 213. [PubMed: 8129633]
71.
Righini A, Antonini A, Ferrarini M, et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. Journal of Computer Assisted Tomography. 2002;26(2):266–271. Ref ID: 129. [PubMed: 11884785]
72.
Seppi K, Schocke MFH, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology. 2003;60(6):922–927. Ref ID: 133. [PubMed: 12654954]
73.
Yekhlef F, Ballan G, Macia F, et al. Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. Journal of Neural Transmission. 2003;110(2):151–169. Ref ID: 135. [PubMed: 12589575]
74.
Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson’s disease. Neuroimage. 2004;23(2):663–669. Ref ID: 19826. [PubMed: 15488416]
75.
Righini A, Antonini A, De Notaris R, et al. MR imaging of the superior profile of the midbrain: Differential diagnosis between progressive supranuclear palsy and Parkinson disease. American Journal of Neuroradiology. 2004;25(6):927–932. Ref ID: 19827. [PMC free article: PMC7975674] [PubMed: 15205125]
76.
Paviour DC, Price SL, Stevens JM, et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2005;64(4):675–679. Ref ID: 19831. [PubMed: 15728291]
77.
Cordato NJ, Pantelis C, Halliday GM, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain. 2002;125(4):789–800. Ref ID: 123. [PubMed: 11912112]
78.
Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. European Journal of Neurology. 2001;8(6):573–577. Ref ID: 17. [PubMed: 11784341]
79.
Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2000;69(5):590–594. Ref ID: 21. [PMC free article: PMC1763425] [PubMed: 11032609]
80.
Rossi P, Colosimo C, Moro E, et al. Acute challenge with apomorphine and levodopa in Parkinsonism. European Neurology. 2000;43(2):95–101. Ref ID: 719. [PubMed: 10686467]
81.
Hughes AJ. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis. Advances in Neurology. 1999;80:363–368. Ref ID: 720. [PubMed: 10410742]
82.
Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990;336(8706):32–34. Ref ID: 84. [PubMed: 1973218]
83.
D’Costa DF, Abbott RJ, Pye IF, et al. The apomorphine test in parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry. 1991;54(10):870–872. Ref ID: 79. [PMC free article: PMC1014569] [PubMed: 1744640]
84.
Zappia M, Montesanti R, Colao R, et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson’s disease. Movement Disorders. 1997;12(1):103–106. Ref ID: 731. [PubMed: 8990062]
85.
Double KL, Rowe DB, Hayes M, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Archives of Neurology. 2003;60(4):545–549. Ref ID: 699. [PubMed: 12707068]
86.
Muller A, Mungersdorf M, Reichmann H, et al. Olfactory function in Parkinsonian syndromes. Journal of Clinical Neuroscience. 2002;9(5):521–524. Ref ID: 700. [PubMed: 12383407]
87.
Wenning GK, Shephard B, Hawkes C, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurologica Scandinavica. 1995;91(4):247–250. Ref ID: 707. [PubMed: 7625148]
88.
Antonini A, Benti R, De Notaris R, et al. 123I-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurological Sciences. 2003;24(3):149–150. Ref ID: 789. [PubMed: 14598060]
89.
Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1997;62(5):436–446. Ref ID: 703. [PMC free article: PMC486843] [PubMed: 9153598]
90.
Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurodegeneration. 1995;4(1):93–97. Ref ID: 708. [PubMed: 7600189]
91.
Katzenschlager R, Zijlmans J, Evans A, et al. Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(12):1749–1752. Ref ID: 19807. [PMC free article: PMC1738844] [PubMed: 15548497]
92.
Mesholam RI, Moberg PJ, Mahr RN, et al. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Archives of Neurology. 1998;55(1):84–90. Ref ID: 702. [PubMed: 9443714]
93.
Mitchell A, Lewis S, Foltynie T, et al. Biomarkers and Parkinson’s disease. Brain. 2004;127:1693–1705. Ref ID: 19536. [PubMed: 15215212]
94.
Clarke CE. A ‘cure’ for Parkinson’s disease: can neuroprotection be proven with current trial designs. Movement Disorders. 2004;19:491–499. Ref ID: 19538. [PubMed: 15133811]
95.
Clarke CE. Parkinson’s disease in practice. London: Royal Society of Medicine Press; 2001. Ref ID: 2.
96.
Schapira A. Disease modification in Parkinson’s disease. Lancet Neurology. 2004;3:362–368. Ref ID: 19537. [PubMed: 15157851]
97.
Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson’s disease. Lancet. 2002;360(9347):1767–1769. Ref ID: 16. [PubMed: 12480442]
98.
Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurology. 2004;3:466–475. Ref ID: 19540. [PubMed: 15261607]
99.
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archives of Neurology. 2004;61(4):561–566. Ref ID: 2764. [PubMed: 15096406]
100.
Ravina BM, Fagan SC, Hart RG. Neuroprotective agents for clinical trials in Parkinson’s disease. Neurology. 2003;60:1234–1240. Ref ID: 19541. [PubMed: 12707423]
101.
Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson’s disease. Parkinson Study Group. Acta Neurologica Scandinavica Supplementum. 1993;146:36–42. Ref ID: 805. [PubMed: 8333252]
102.
Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson’s disease. Neurology. 1994;44(9):1756–1759. Ref ID: 281. [PubMed: 7936311]
103.
Koller W, Olanow CW, Rodnitzky R, et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine. 1993;328(3):176–183. Ref ID: 148. [PubMed: 8417384]
104.
Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurologica Scandinavica Supplementum. 1989;80(126):171–175. Ref ID: 363. [PubMed: 2515723]
105.
Parker W, Boyson S, Parks J. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Annals of Neurology. 1989;26:719–723. Ref ID: 19543. [PubMed: 2557792]
106.
Schapira A, Mann V, Cooper J. Anatomic and disease specificity of NADH CoQ1 reductase (complex 1) deficiency in Parkinson’s disease. Journal of Neurochemistry. 1990;55:2142–2145. Ref ID: 19544. [PubMed: 2121905]
107.
Shults C, Haas R, Passov D, et al. Coenzyme Q10 levels correlate with the activities of the complex I and II/III mitochrondria from parkinsonian and non-parkinsonian subjects. Annals of Neurology. 1997;42:261–264. Ref ID: 19545. [PubMed: 9266740]
108.
Beal MF, Matthews R, Tieleman A, et al. Coenzyme Q10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Research. 1998;783:109–114. Ref ID: 19546. [PubMed: 9479058]
109.
Muller T, Buttner T, Gholipour AF, et al. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neuroscience Letters. 2003;341(3):201–204. Ref ID: 799. [PubMed: 12697283]
110.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology. 2002;59(10):1541–1550. Ref ID: 801. [PubMed: 12374491]
111.
Lida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Research. 1999;838:51–59. Ref ID: 19547. [PubMed: 10446316]
112.
Schapira A, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson’s disease. Annals of Neurology. 2003;53:S149–157. Ref ID: 19549. [PubMed: 12666106]
113.
Marek K. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Journal of the American Medical Association. 2002;287(13):1653–1661. Ref ID: 809. [PubMed: 11926889]
114.
Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. Journal of Neural Transmission. 2002;109(12):1433–1443. Ref ID: 2535. [PubMed: 12486484]
115.
Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. European Journal of Clinical Pharmacology. 1992;43(4):357–363. Ref ID: 2518. [PubMed: 1451713]
116.
Hely MA, Morris JG, Traficante R, et al. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. Journal of Neurology, Neurosurgery & Psychiatry. 1999;67(3):300–307. Ref ID: 2184. [PMC free article: PMC1736543] [PubMed: 10449550]
117.
Montastruc JL, Desboeuf K, Lapeyre-Mestre M, et al. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson’s disease. Movement Disorders. 2001;16(3):511–514. Ref ID: 2414. [PubMed: 11391747]
118.
Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with Cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs. 1998;55(Suppl 1):23–3T. xCM 20. Ref ID: 19605. [PubMed: 9483167]
119.
Hundemer HP, Lledo A, Van Laar T, et al. The safety of pergolide monotherapy in early stage Parkinson’s disease. One year interim analysis of a 3 year double blind randomised study of pergolide versus levodopa (abstract). Movement Disorders. 2000;15(Supplement 3):115. Ref ID: 19598.
120.
Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinsons’s disease: meta analysis of 17 randomised trials involving 3525 patients. British Medical Journal. 2004;329(7466):593–596. Ref ID: 2739. [PMC free article: PMC516655] [PubMed: 15310558]
121.
Macleod AD, Counsell CE, Ives N, et al. Monoamine oxidase B inhibitors for early Parkinson’s disease. The Cochrane Database of Systematic Reviews. 2005;(3):CD004898. Ref ID: 20026. [PMC free article: PMC8859569] [PubMed: 16034956]
122.
Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology. 1999;53(3):573–579. Ref ID: 1937. [PubMed: 10449123]
123.
Kieburtz K. Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study. Journal of the American Medical Association. 1997;278(2):125–130. Ref ID: 1501. [PubMed: 9214527]
124.
Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology. 1997;49(2):393–399. Ref ID: 1902. [PubMed: 9270567]
125.
Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology. 1997;49(3):724–728. Ref ID: 19764. [PubMed: 9305331]
126.
Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clinical Neuropharmacology. 1995;18(4):338–347. Ref ID: 19643. [PubMed: 8665547]
127.
Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s disease. Clinical Neuropharmacology. 1998;21(2):101–107. Ref ID: 1977. [PubMed: 9579296]
128.
Committee on Safety of Medicines. Fibrotic reactions with pergolide and other ergot-derived dopamine receptor agonists. Current Problems in Pharmacovigilance. 2002;28(3) Ref ID: 19899.
129.
Baseman D, O’Suilleabhain P. Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology. 2004;63:301–304. Ref ID: 19900. [PubMed: 15277624]
130.
Van Camp G, Flamez A. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179–1183. Ref ID: 19901. [PubMed: 15081648]
131.
Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: a long-term study. Journal of Neural Transmission. 1985;64:113–127. Ref ID: 19677. [PubMed: 3935752]
132.
Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Movement Disorders. 2004;19(8):916–923. Ref ID: 19854. [PubMed: 15300656]
133.
Presthus J, Berstad J, Lien K. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson’s disease. A double-blind crossover trial. Acta Neurologica Scandinavica. 1987;76:200–203. Ref ID: 2761. [PubMed: 3120487]
134.
Crosby NJ, Deane HO, Clarke CE. Beta-blocker therapy for tremor in Parkinson’s disease.(Cochrane Review). The Cochrane Database of Systematic Reviews. 2003;(1):CD003361. Ref ID: 80. [PMC free article: PMC8713552] [PubMed: 12535472]
135.
Marsden CD, Parkes JD, Rees JE. Propanolol in Parkinson’s disease. Lancet. 1974;2(7877):410. Ref ID: 19533. [PubMed: 4136980]
136.
Corbett JL. Beta blockers and the central nervous system. An International Symposium. In: Kielkholz P, editor. Bern: Huber; 1976. pp. 200–217. Ref ID: 19534.
137.
Henderson JM, Yiannikas C, Morris JG, et al. Postural tremor of Parkinson’s disease. Clinical Neuropharmacology. 1994;17(3):277–285. Ref ID: 755. [PubMed: 9316673]
138.
Claveria L, Vakil S, George C, et al. Oxprenolol in Parkinsonism. The Journal of Clinical Pharmacology. 1975;15(1):66–68. Ref ID: 19532.
139.
Crosby N, Deane KHO, Clarke CE. Amantadine in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2003;(1):CD003468. Ref ID: 51. [PMC free article: PMC8715353] [PubMed: 12535476]
140.
Cox B, Danta G, Schnieden H, et al. Interactions of L-dopa and amantadine in patients with Parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry. 1973;36(3):354–361. Ref ID: 19645. [PMC free article: PMC494333] [PubMed: 4714097]
141.
Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Diseases of the Nervous System. 1977;38(8):605–608. Ref ID: 19552. [PubMed: 328244]
142.
Walker JE, Albers JW, Tourtellotte WW, et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson’s disease. Journal of Chronic Diseases. 1972;25:149–182. Ref ID: 19556. [PubMed: 4555278]
143.
Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2002;(3):CD003735. Ref ID: 92. [PMC free article: PMC8728160] [PubMed: 12804486]
144.
Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. Brain. 1992;115(6):1701–1725. Ref ID: 19567. [PubMed: 1486457]
145.
Parkes JD, Baxter RC, Marsden CD, et al. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1974;37(4):422–426. Ref ID: 19569. [PMC free article: PMC494673] [PubMed: 4838913]
146.
Hutton JT, Lynne DR, Bianchine JR. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism. Clinical Neuropharmacology. 1984;7(2):135–139. Ref ID: 783. [PubMed: 6375861]
147.
Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurologica Scandinavica. 1996;93(1):14–20. Ref ID: 778. [PubMed: 8825266]
148.
Kinnunen E, Asikaimen I, Jolma T, et al. Three-year open comparison of standard and sustained-release levodopa/benserazide preparations in newly diagnosed Parkinsonian patients. Focus on Parkinson’s Disease. 1997;9(2):32–36. Ref ID: 304.
149.
Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release Carbidopa/Levodopa in Parkinson’s disease. A multicenter 5-year study. European Neurology. 1997;37(1):23–27. Ref ID: 257. [PubMed: 9018028]
150.
Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Annals of Neurology. 1995;38:771–777. Ref ID: 2746. [PubMed: 7486869]
151.
Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease. Neurology. 1993;43(1):21–27. Ref ID: 2718. [PubMed: 8423888]
152.
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. New England Journal of Medicine. 2000;342(20):1484–1491. Ref ID: 2540. [PubMed: 10816186]
153.
Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. Journal of Neurology, Neurosurgery & Psychiatry. 1994;57(8):903–910. Ref ID: 2185. [PMC free article: PMC1073071] [PubMed: 8057111]
154.
Herskovits E, Yorio A, Leston J. Long term bromocriptine treatment in de novo parkinsonian patients. Medicina. 1988;48(4):345–350. Ref ID: 2193. [PubMed: 3076200]
155.
Riopelle RJ, Gawel MJ, Libman I, et al. A double-blind study of bromocriptine and L-dopa in de novo Parkinson’s disease. Short-term results. European Neurology. 1988;28(SUPPL 1):11–14. Ref ID: 1048. [PubMed: 3288477]
156.
Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson’s disease. A randomized multicenter study. Parkinsonism & Related Disorders. 2001;7(2):107–114. Ref ID: 324. [PubMed: 11248591]
157.
Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Movement Disorders. 2000;15(4):613–626. Ref ID: 2287. [PubMed: 10928571]
158.
Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of Neurology. 2004;61(7):1044–1053. Ref ID: 19842. [PubMed: 15262734]
159.
Allain H, Destee A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. European Neurology. 2000;44(1):22–30. Ref ID: 1914. [PubMed: 10894991]
160.
Gimenez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson’s disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clinical Neuropharmacology. 1997;20(1):67–76. Ref ID: 2136. [PubMed: 9037575]
161.
Alarcon F, Cevallos N, Lees AJ. Does combined levodopa and bromocriptine therapy in Parkinson’s disease prevent late motor complications? European Journal of Neurology. 1998;5(3):255–263. Ref ID: 1274. [PubMed: 10210840]
162.
Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. Journal of Neural Transmission. 1996;103(6):699–715. Ref ID: 2520. [PubMed: 8836932]
163.
Ramaker C, Hilten JV. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson’s disease. (Cochrane Review). The Cochrane Database of Systematic Reviews. 2002;(2):CD003634. Ref ID: 42. [PubMed: 12076493]
164.
Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics. 1998;14(5):541–557. Ref ID: 19750. [PubMed: 10344917]
165.
Noyes K, Dick AW, Holloway RG. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trial. Med Decision Making. 2004;24(5):472–485. Ref ID: 19763. [PubMed: 15358996]
166.
Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson’s disease. Pharmacoeconomics. 2003;21(2):115–127. Ref ID: 19745. [PubMed: 12515573]
167.
Smala AM, Spottke EA, Machat O, et al. Cabergoline versus levodopa monotherapy: a decision analysis. Movement Disorders. 2003;18(8):898–905. Ref ID: 19754. [PubMed: 12889079]
168.
Lindgren P, Jonsson B, DuChane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. European Journal of Health Economics. 2003;4(1):37–42. Ref ID: 19853. [PubMed: 15609167]
169.
Noyes K, Dick AW, Holloway RG. Pramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectiveness. Pharmacoeconomics. 2005;23(12):1257–1270. Ref ID: 20122. [PubMed: 16336019]
170.
Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson’s disease and fluctuating motor performance. Journal of Neurology, Neurosurgery & Psychiatry. 1989;52(2):207–212. Ref ID: 261. [PMC free article: PMC1032507] [PubMed: 2649640]
171.
Hutton JT, Morris JL, Bush DF, et al. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson’s disease. Neurology. 1989;39(11 SUPPL 2):67–72. Ref ID: 293. [PubMed: 2685652]
172.
Hutton JT, Morris JL, Roman GC, et al. Treatment of chronic Parkinson’s disease with controlled-release carbidopa/levodopa. Archives of Neurology. 1988;45(8):861–864. Ref ID: 295. [PubMed: 3395259]
173.
LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): Clinical and pharmacokinetic studies. Neurology. 1989;39(11 SUPPL 2):45–53. Ref ID: 310. [PubMed: 2685650]
174.
Feldman RG, Mosbach PA, Kelly MR, et al. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson’s disease. Neurology. 1989;39(11 SUPPL 2):96–101. Ref ID: 277. [PubMed: 2685655]
175.
Lieberman A, Gopinathan G, Miller E, et al. Randomized double-blind cross-over study of sinemet-controlled release (CR4 50/200) versus sinemet 25/100 in Parkinson’s disease. European Neurology. 1990;30(2):75–78. Ref ID: 157. [PubMed: 2340838]
176.
Wolters EC, Horstink MW, Roos RA, et al. Clinical efficacy of sinemet CR 50/200 versus sinemet 25/100 in patients with fluctuating Parkinson’s disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. Clinical Neurology & Neurosurgery. 1992;94:205–211. Ref ID: 775. [PubMed: 1327609]
177.
Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson’s disease. Journal of Neurology. 1996;243(3):235–240. Ref ID: 19640. [PubMed: 8936353]
178.
Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson’s disease: A double-blind, crossover study. Clinical Neuropharmacology. 1988;11(2):174–179. Ref ID: 348. [PubMed: 3378226]
179.
Juncos JL, Fabbrini G, Mouradian MM, et al. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. Archives of Neurology. 1987;44(10):1010–1012. Ref ID: 109. [PubMed: 3632371]
180.
Ahlskog JE, Muenter MD, McManis PG, et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clinic Proceedings. 1988;63(9):876–886. Ref ID: 248. [PubMed: 3045435]
181.
Hammerstad JP, Carter J, Nutt JG. Buspirone in Parkinson’s disease. Clinical Neuropharmacology. 1986;9(6):556–560. Ref ID: 401. [PubMed: 3026624]
182.
Van Hilten JJ, Ramaker C, van de Beek WJT, et al. Bromocriptine for levodopa-induced motor complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 1998;(3):CD001203. Ref ID: 47. [PMC free article: PMC7032627] [PubMed: 10796755]
183.
Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2001;(1):CD001518. Ref ID: 52. [PMC free article: PMC8406784] [PubMed: 11279720]
184.
Clarke CE, Speller JM. Lisuride for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 1999;(1):CD001515. Ref ID: 54. [PMC free article: PMC7025784] [PubMed: 10796801]
185.
Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 1999;(2):CD000235. Ref ID: 56. [PubMed: 10796704]
186.
Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2000;(2):CD002261. Ref ID: 58. [PMC free article: PMC8406669] [PubMed: 10908540]
187.
Clarke CE, Deane KHO. Ropinirole for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2001;(1):CD001516. Ref ID: 60. [PubMed: 11279718]
188.
Pogarell O, Gasser T, Van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology, Neurosurgery & Psychiatry. 2002;72(6):713–720. Ref ID: 2512. [PMC free article: PMC1737934] [PubMed: 12023411]
189.
Wong KS, Lu C-S, Shan D-E, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. Journal of the Neurological Sciences. 2003;216(1):81–87. Ref ID: 1823. [PubMed: 14607306]
190.
Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Movement Disorders. 2003;18(10):1149–1156. Ref ID: 2405. [PubMed: 14534919]
191.
Guttman M. The International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology. 1997;49(4):1060–1065. Ref ID: 19602. [PubMed: 9339690]
192.
Bateman DN, Coxon A, Legg NJ, et al. Treatment of the on-off syndrome in parkinsonism with low-dose bromocriptine in combination with levodopa. Journal of Neurology, Neurosurgery & Psychiatry. 1978;41(12):1109–1113. Ref ID: 19614. [PMC free article: PMC493239] [PubMed: 366085]
193.
Gron U. Bromocriptine versus placebo in levodopa treated patients with Parkinson’s disease. Acta Neurologica Scandinavica. 1977;56(3):269–273. Ref ID: 19615. [PubMed: 333855]
194.
Maier-Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson’s disease. Neurology. 1985;35:199–206. Ref ID: 434. [PubMed: 3969207]
195.
Jansen EN. Bromocrytine in levodopa response-losing parkinsonism. European Neurology. 1978;17:92–99. Ref ID: 19617. [PubMed: 344042]
196.
Schneider E, Fischer PA. Bromocriptin in der Behandlung der fortgeschrittenen Stadien des Parkinson-syndroms [German] Deutsche Medizinische Wochenschrift. 1982;107:175–179. Ref ID: 19618. [PubMed: 6799266]
197.
Temlett JA, Ming A, Saling M, et al. Adjunctive therapy with bromocriptine in Parkinson’s disease. South African Medical Journal. 1990;78:680–685. Ref ID: 19620. [PubMed: 2251616]
198.
Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine in parkinsonism: a nation-wide collaborative double-blind study. Acta Neurologica Scandinavica. 1985;72:157–170. Ref ID: 19623. [PubMed: 3901650]
199.
Miguel F, Obeso JA, Olive Plana JM, et al. Double-blind parallel group study of the efficacy and tolerability of the cabergoline vs placebo in Parkinson’s patients with motor fluctuations. (21336/722i). FCE report. 1993. Ref ID: 19609.
200.
Steiger MJ, El Debas T, Anderson T, et al. Double-blind study of the activity and tolerablility of cabergoline versus placebo in parkinsonains with motor fluctuations. Journal of Neurology. 1996;243:68–72. Ref ID: 19610. [PubMed: 8869390]
201.
Hutton JT, Koller WC, Ahlskog JE, et al. Multicentre, placebo-controlled trials of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology. 1996;46:1062–1065. Ref ID: 19608. [PubMed: 8780092]
202.
Olanow CW, Fahn S, Muenter M, et al. A multi-centre double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Movement Disorders. 1994;9:40–47. Ref ID: 19607. [PubMed: 8139604]
203.
Lieberman A, Ranhosky A, Korts D. Clinical Evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162–168. Ref ID: 19603. [PubMed: 9222185]
204.
Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double-blind, placebo-controlled, randomised, multi-centre study. Journal of Neurology, Neurosurgery & Psychiatry. 1999;66:436–441. Ref ID: 19604. [PMC free article: PMC1736320] [PubMed: 10201413]
205.
Wermuth L. The Danish Pramipexole Study Group. A double-blind, placebo-controlled, randomised, multi-centre study of pramipexole in advanced Parkinson’s disease. European Journal of Neurology. 1998;5:235–242. Ref ID: 19606. [PubMed: 10210837]
206.
Rascol O, Lees AJ, Senard JM, et al. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Advances in Neurology. 1996;69:531–534. Ref ID: 19601. [PubMed: 8615176]
207.
Leiberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology. 1998;51:1057–1062. Ref ID: 19612. [PubMed: 9781529]
208.
Korcyn AD. Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in Parkinsonian patients not optimally controlled in L-dopa. (MY-1002/SKF-101468/2/CPMS-034). SmithKline Beecham Pharmaceuticals; 1990. Unpublished data. Ref ID: 19611.
209.
Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders. 2004;19(4):426–432. Ref ID: 428. [PubMed: 15077240]
210.
Brodersen P, Philbert A, Gulliksen G, et al. The effect of l-deprenyl on on-off phenomena in Parkinson’s disease. Acta Neurologica Scandinavica. 1985;71:494–497. Ref ID: 2762. [PubMed: 3927650]
211.
Presthus J, Hajba A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson’s disease. Acta Neurologica Scandinavica Supplementum. 1983;95:127–133. Ref ID: 477. [PubMed: 6428145]
212.
Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clinical Neuropharmacology. 1988;11(1):45–55. Ref ID: 510. [PubMed: 3127050]
213.
Golbe LI, Duvoisin RC. Double-blind trial of R-deprenyl for the “on-off” effect complicating Parkinson’s disease. Journal of Neural Transmission Supplementum. 1987;25:123–129. Ref ID: 2760. [PubMed: 3123598]
214.
Hubble JP, Koller WC, Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson’s disease. Clinical Neuropharmacology. 1993;16:83–87. Ref ID: 2752. [PubMed: 8422661]
215.
Sivertsen B, Dupont E, Mikkelsen B, et al. Selegiline and levodopa in early or moderately advanced Parkinson’s disease: A double-blind controlled short- and long-term study. Acta Neurologica Scandinavica Supplementum. 1989;80(126):147–152. Ref ID: 193. [PubMed: 2515720]
216.
Lieberman AN, Gopinathan G, Neophytides A, et al. Deprenyl versus placebo in Parkinson disease: a double-blind study. New York State Journal of Medicine. 1987;87:646–649. Ref ID: 88. [PubMed: 3124027]
217.
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in Parkinson’s disease patients with motor fluctuations (LARGO study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947–954. Ref ID: 19840. [PubMed: 15766996]
218.
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Archives of Neurology. 2005;62(2):241–248. Ref ID: 19833. [PubMed: 15710852]
219.
Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson’s disease. Pharmacology and Therapeutics. 1999;81(1):1–36. Ref ID: 19766. [PubMed: 10051176]
220.
Myllyla V, Haapaniemi TH, Kaakkola S, et al. New triple combination levodopa/carbidopa/entacapone is a preferred treatment in patients in Parkinson’s disease (abstract). Neurology. 2003;60(suppl 1):A289. Ref ID: 20027.
221.
Deane KHO, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2004;(4):CD004554. Ref ID: 19624. [PMC free article: PMC8830033] [PubMed: 15495119]
222.
Reichmann H, Boas J, Macmahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurologica Scandinavica. 2005;111(1):21–28. Ref ID: 19864. [PubMed: 15595934]
223.
Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Archives of Neurology. 2004;61(10):1563–1568. Ref ID: 104. [PubMed: 15477510]
224.
Brooks DJ, Sagar HJ. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease. A randomized, placebo-controlled, double-blind six month study. Journal of Neurology, Neurosurgery & Psychiatry. 2003;74:1071–1079. Ref ID: 19670. [PMC free article: PMC1738605] [PubMed: 12876237]
225.
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Annals of Neurology. 1997;42(5):747–755. Ref ID: 19637. [PubMed: 9392574]
226.
Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6 month randomised placebo-controlled double-blind study in Germany and Austria (Celomen Study). Acta Neurologica Scandinavica. 2004;105:245–255. Ref ID: 19674. [PubMed: 11939936]
227.
Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51(5):1309–1314. Ref ID: 19638. [PubMed: 9818851]
228.
Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. Journal of Neurology, Neurosurgery & Psychiatry. 1996;60(1):36–40. Ref ID: 19636. [PMC free article: PMC486187] [PubMed: 8558148]
229.
Fenelon G, Bourdiex I, Pere J, Galiano L, Shadarack J. Entacapone provides additional symptomatic benefits in Parkinson’s disease (PD) patients treated with L-DOPA and a dopamine agonist who are experiencing wearing-off motor fluctuations: results of a randomised, double-blind study. AAN conference. 2002. Ref ID: 19671.
230.
Im JH, Jeon BS, Lee MS, et al. A multicentre, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson’s disease experiencing end-of-dose deterioration. Movement Disorders. 2002;17(5):S40. Ref ID: 19672.
231.
Myllyla VV, Kultalahti E-R, Haapaniemi H, et al. Twelve-month safety of entacapone patients with Parkinson’s disease. European Journal of Neurology. 2001;8:53–60. Ref ID: 19673. [PubMed: 11509081]
232.
Adler CH, Singer C, O’Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Archives of Neurology. 1998;55(8):1089–1095. Ref ID: 19634. [PubMed: 9708959]
233.
Baas H, Beiske A, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduced the ‘wearing-off’ phenomenon and levodopa requirements in fluctuating Parkinsonian patients. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63(4):421–428. Ref ID: 19669. [PMC free article: PMC2169755] [PubMed: 9343116]
234.
Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Movement Disorders. 1997;12(6):928–934. Ref ID: 19631. [PubMed: 9399217]
235.
Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48(1):81–87. Ref ID: 19633. [PubMed: 9008498]
236.
Myllyla VV, Jackson M, Larsen JP, et al. Efficacy and safety of tolcapone in levodopa-treated Parkinson’s disease patients with ‘wearing-off’ phenomenon: A multicentre, double-blind, randomized, placebo-controlled trial. European Journal of Neurology. 1997;4(4):333–341. Ref ID: 19639.
237.
Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49(4):1066–1071. Ref ID: 19632. [PubMed: 9339691]
238.
Crosby NJ, Deane HO, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. (Cochrane Review). The Cochrane Database of Systematic Reviews. 2003;(2):CD003467. Ref ID: 50. [PMC free article: PMC8715285] [PubMed: 12804468]
239.
Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(1):141–143. Ref ID: 318. [PMC free article: PMC1757492] [PubMed: 14707325]
240.
Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement Disorders. 2000;15(5):873–878. Ref ID: 152. [PubMed: 11009193]
241.
Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: A double-blind, placebo-controlled study. Clinical Neuropharmacology. 2000;23(2):82–85. Ref ID: 311. [PubMed: 10803797]
242.
Verhagen ML, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50(5):1323–1326. Ref ID: 19594. [PubMed: 9595981]
243.
Dewey RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Archives of Neurology. 2001;58(9):1385–1392. Ref ID: 19655. [PubMed: 11559309]
244.
Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery & Psychiatry. 1995;58(6):681–687. Ref ID: 19628. [PMC free article: PMC1073544] [PubMed: 7608665]
245.
Van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson’s disease. Clinical Neurology & Neurosurgery. 1993;95(3):231–235. Ref ID: 19992. [PubMed: 8242966]
246.
Poewe W, Kleedorfer B, Wagner M, et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients. Advances in Neurology. 1993;60:656–659. Ref ID: 19651. [PubMed: 8420206]
247.
Kanovsky P, Kubova D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Movement Disorders. 2002;17(1):188–191. Ref ID: 19656. [PubMed: 11835461]
248.
Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1990;53(2):96–101. Ref ID: 19731. [PMC free article: PMC487943] [PubMed: 2313313]
249.
Stocchi F, Vacca L, De Pandis MF, et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurological Sciences. 2001;22(1):93–94. Ref ID: 19733. [PubMed: 11487217]
250.
Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. Journal of Neurology, Neurosurgery & Psychiatry. 1998;65(5):709–716. Ref ID: 19734. [PMC free article: PMC2170363] [PubMed: 9810943]
251.
Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Movement Disorders. 1993;8(2):165–170. Ref ID: 19735. [PubMed: 8474483]
252.
Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: Clinical utility and lack of tolerance. Movement Disorders. 1995;10(1):37–43. Ref ID: 19737. [PubMed: 7885354]
253.
Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Movement Disorders. 2002;17(6):1235–1241. Ref ID: 19730. [PubMed: 12465062]
254.
Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(5):573–576. Ref ID: 19736. [PMC free article: PMC2170072] [PubMed: 9598668]
255.
Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Movement Disorders. 2005;20(2):151–157. Ref ID: 19993. [PubMed: 15390035]
256.
Deane KHO, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2004;(4):CD004553. Ref ID: 19625. [PMC free article: PMC8829897] [PubMed: 15495118]
257.
Koller W, Lees A, Doder M, et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Movement Disorders. 2001;16(5):858–866. Ref ID: 307. [PubMed: 11746615]
258.
Agid Y, Destee A, Durif F, et al. Tolcapone, bromocriptine and Parkinson’s disease. Lancet. 1997;350:712–713. Ref ID: 217. [PubMed: 9291909]
259.
Lenz FA, Tasker RR, Kwan HC, et al. Selection of the optimal lesion site for the relief of parkinsonian tremor on the basis of spectral analysis of neuronal firing patterns. Applied Neurophysiology. 1987;50:1–6. 338–43. Ref ID: 19843. [PubMed: 3329872]
260.
Cooper IS. Anterior chorodial artery ligation for involuntary movements. Science. 1953;118(3059):193. Ref ID: 19844. [PubMed: 13076243]
261.
Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. Journal of Neurosurgery. 1992;76:53–61. Ref ID: 19845. [PubMed: 1727169]
262.
Huntington’s Outreach Project for Education at Stanford. Basal Ganglia. [accessed 20 April 2006]. Available from: www​.stanfordedu/group/hopes/ Ref ID: 19939.
263.
Aziz TZ, Peggs D, Sambrook MA, et al. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Movement Disorders. 1991;6(4):288–292. Ref ID: 19846. [PubMed: 1758446]
264.
Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436–1438. Ref ID: 19847. [PubMed: 2402638]
265.
Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345(8942):91–95. Ref ID: 19848. [PubMed: 7815888]
266.
Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. Journal of Neurology. 2002;249(6):759–766. Ref ID: 19713. [PubMed: 12111311]
267.
Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: A cost-effectiveness analysis. Neurology. 2001;57(4):663–671. Ref ID: 19714. [PubMed: 11524476]
268.
McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: The case for subthalamic nucleus stimulation in the treatment of advanced Parkinson’s disease. Movement Disorders. 2003;18(9):993–999. Ref ID: 404. [PubMed: 14502666]
269.
Charles PD, Padaliya BB, Newman WJ, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism & Related Disorders. 2004;10(8):475–479. Ref ID: 19708. [PubMed: 15542007]
270.
Lagrange E, Krack P, Moro E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology. 2002;59(12):1976–1978. Ref ID: 386. [PubMed: 12499496]
271.
Welter ML, Houeto JL, Tezenas du MS, et al. Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain. 2002;125(3):575–583. Ref ID: 19700. [PubMed: 11872614]
272.
Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Movement Disorders. 2003;18(11):1332–1337. Ref ID: 19698. [PubMed: 14639676]
273.
Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(6):834–839. Ref ID: 19707. [PMC free article: PMC1739075] [PubMed: 15145995]
274.
Tavella A, Bergamasco B, Bosticco E, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: Long-term follow-up. Neurological Sciences. 2002;23(suppl 2):S111–112. Ref ID: 389. [PubMed: 12548368]
275.
Russmann H, Ghika J, Villemure JG, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology. 2004;63(10):1952–1954. Ref ID: 19727. [PubMed: 15557522]
276.
Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. New England Journal of Medicine. 2003;349(20):1925–1934. Ref ID: 19699. [PubMed: 14614167]
277.
Limousin P, Speelman JD, Gielen F, et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. Journal of Neurology, Neurosurgery & Psychiatry. 1999;66(3):289–296. Ref ID: 19703. [PMC free article: PMC1736277] [PubMed: 10084526]
278.
Vesper J, Klostermann F, Wille C, et al. Long-term suppression of extrapyramidal motor symptoms with deep brain stimulation (DBS). German Journal of Neurosurgery. 2004;65(3):117–122. Ref ID: 400. [PubMed: 15306975]
279.
Obeso JA, Guridi J, Rodriguez-Oroz MC, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New England Journal of Medicine. 2001;345(13):956–963. Ref ID: 417. [PubMed: 11575287]
280.
Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology. 2001;56(4):548–551. Ref ID: 19701. [PubMed: 11222806]
281.
Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: A consecutive series of 62 patients. Annals of Neurology. 1999;46(2):217–223. Ref ID: 19702. [PubMed: 10443887]
282.
Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson’s disease: target related effect or selection bias? Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(1):34–39. Ref ID: 19885. [PMC free article: PMC1739322] [PubMed: 15607992]
283.
Ondo W, Dat VK, Almaguer M, et al. Thalamic deep brain stimulation: effects on the nontarget limbs. Movement Disorders. 2001;16(6):1137–1142. Ref ID: 19704. [PubMed: 11748749]
284.
Benabid AL, Pollak P, Seigneuret E, et al. Chronic VIM thalamic stimulation in Parkinson’s disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurgica Supplement (Wien). 1993;58:39–44. Ref ID: 19728. [PubMed: 8109299]
285.
Krauss JK, Simpson RK Jr, Ondo WG, et al. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001;48(3):535–541. Ref ID: 19705. [PubMed: 11270543]
286.
Karlsen KH, Larsen JP, et al. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1999;66(4):431–435. Ref ID: 19758. [PMC free article: PMC1736304] [PubMed: 10201412]
287.
Hely MA, Morris JG, Reid J, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Movement Disorders. 2005;20(2):190–199. Ref ID: 19892. [PubMed: 15551331]
288.
Chaudhuri KR, Schapira A, Martinez-Martin P, et al. The holisitic management of Parkinsons’ disease using a novel non-motor symptom scale and questionnaire. Advances in Clinical Neurosciences and Rehabilitation. 2004;4:20–24. Ref ID: 19893.
289.
Goetz CG, Koller WC, Poewe W, et al. Treatment of depression in idiopathic Parkinson’s disease. Movement Disorders. 2002;17(suppl 4):S112–119. Ref ID: 19760. [PubMed: 12211151]
290.
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology, Neurosurgery & Psychiatry. 2000;69:308–312. Ref ID: 19887. [PMC free article: PMC1737100] [PubMed: 10945804]
291.
Shabnam G, Chung TH, Deane KHO, et al. Therapies for depression in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2003;(2):CD003465. Ref ID: 78. [PubMed: 12917968]
292.
Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(8):1171–1174. Ref ID: 19761. [PMC free article: PMC1739189] [PubMed: 15258224]
293.
Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson’s disease. International Journal of Geriatric Psychiatry. 2003;18(6):552–554. Ref ID: 19762. [PubMed: 12789682]
294.
Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram. A placebo-controlled trial. Nordic Journal of Psychiatry. 1998;52(2):163–169. Ref ID: 19772.
295.
Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta Neurologica Scandinavica. 1980;62(4):210–219. Ref ID: 19771. [PubMed: 7010875]
296.
Rabey J, Orlov E, Korczyn A. Comparison of fluvoamine versus amitriptyline for treatment of depression in Parkinson’s disease. Neurology. (Abstract). 1996;46:A374. Ref ID: 19788.
297.
Jiménez-Jiménez FJ, Tejeiro J, Martinez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology. 1994;44(12):2406. Ref ID: 19895. [PubMed: 7991139]
298.
Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology. 1997;48(4):1070–1077. Ref ID: 20123. [PubMed: 9109902]
299.
Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733–745. Ref ID: 19888. [PubMed: 10734005]
300.
Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63:434–440. Ref ID: 19889. [PMC free article: PMC2169767] [PubMed: 9343119]
301.
Friedman J, Lannon M, Cornelia C, et al. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. New England Journal of Medicine. 1999;340(10):757–763. Ref ID: 19775. [PubMed: 10072410]
302.
Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Movement Disorders. 2002;17(5):1031–1035. Ref ID: 19778. [PubMed: 12360554]
303.
Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biological Psychiatry. 2002;52(5):438–445. Ref ID: 19776. [PubMed: 12242060]
304.
Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(5):689–695. Ref ID: 19779. [PMC free article: PMC1763590] [PubMed: 15090561]
305.
Ondo W, Tintner R, Dat VK, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Movement Disorders. 2005;20(8):958–963. Ref ID: 19933. [PubMed: 15800937]
306.
Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55(6):789–794. Ref ID: 264. [PubMed: 10993997]
307.
Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clinical Neuropharmacology. 2004;27(4):153–156. Ref ID: 290. [PubMed: 15319699]
308.
Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. Journal of Neuropsychiatry & Clinical Neurosciences. 2000;12(3):364–369. Ref ID: 19781. [PubMed: 10956570]
309.
Bain PG. The management of tremor. Neurology in Practice. 2002;72(5 suppl 1):i3–i9. Ref ID: 2727. [PMC free article: PMC1765579] [PubMed: 11870197]
310.
Message from Professor Gordon Duff, Chairman Committee on Safety of Medicines. Atypical antipsychotic drugs and stroke. Available from: www​.mhra.gov.uk/home. Date of message: 3 September 2004. Ref ID: 19907.
311.
Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson’s disease: an 8 year prospective study. Archives of Neurology. 2003;60:387–392. Ref ID: 19890. [PubMed: 12633150]
312.
Aarsland D, Larsen JP, Karlsen KH, et al. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. International Journal of Geriatric Psychiatry. 1999;14:866–874. Ref ID: 19891. [PubMed: 10521886]
313.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. New England Journal of Medicine. 2004;351(24):2509–2518. Ref ID: 231. [PubMed: 15590953]
314.
Leroi I, Brandt J, Reich S, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. International Journal of Geriatric Psychiatry. 2004;19(1):1–8. Ref ID: 243. [PubMed: 14716693]
315.
Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, et al. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. International Journal of Geriatric Psychiatry. 2003;18(10):879–886. Ref ID: 19981. [PubMed: 14533120]
316.
Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(7):934–939. Ref ID: 19948. [PMC free article: PMC1739697] [PubMed: 15965198]
317.
Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson’s disease: A randomised controlled study. Journal of Neurology, Neurosurgery & Psychiatry. 2002;72(6):708–712. Ref ID: 19965. [PMC free article: PMC1737925] [PubMed: 12023410]
318.
Giladi N, Shabtai H, Gurevich T, et al. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurologica Scandinavica. 2003;108(5):368–373. Ref ID: 19967. [PubMed: 14616309]
319.
Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. International Journal of Geriatric Psychiatry. 2003;18(10):937–941. Ref ID: 19958. [PubMed: 14533126]
320.
Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies (Cochrane Review). The Cochrane Database of Systematic Reviews. 2003;(3):CD003672. Ref ID: 19787. [PMC free article: PMC7389676] [PubMed: 12917981]
321.
McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–2036. Ref ID: 208. [PubMed: 11145488]
322.
Barone P, Amboni M, Vitale C, et al. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson’s disease. Neurology. 2004;63(8 Suppl 3):S35–38. Ref ID: 19898. [PubMed: 15505142]
323.
Chaudhuri KR, Forbes A, Grosset DG, et al. Diagnosing restless legs syndrome (RLS) in primary care. Current Medical Research Opinion. 2004;20(11):1785–1795. Ref ID: 19902. [PubMed: 15537479]
324.
Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–1910. Ref ID: 19896. [PubMed: 10371546]
325.
Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Movement Disorders. 2003;18(3):287–293. Ref ID: 2780. [PubMed: 12621632]
326.
Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–909. Ref ID: 2781. [PubMed: 12489899]
327.
Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(12):1636–1639. Ref ID: 20116. [PMC free article: PMC1739456] [PubMed: 16291885]
328.
The UK Madopar CR Study Group. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson’s disease. Clinical Neuropharmacology. 1989;12(6):498–505. Ref ID: 19641. [PubMed: 2691069]
329.
Ashburn A, Stack E, Pickering RM, et al. A community-dwelling sample of people with Parkinson’s disease: characteristics of fallers and non-fallers. Age & Ageing. 2001;30:47–52. Ref ID: 19858. [PubMed: 11322672]
330.
Schrag A, Ben Shlomo Y, Quinn N. How common are the complications of Parkinson’s disease? Journal of Neurology. 2002;294(4):419–423. Ref ID: 19859. [PubMed: 11967646]
331.
Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in post-mortem-confirmed Parkinsonian disorders. Movement Disorders. 2001;14(6):947–950. Ref ID: 19860. [PubMed: 10584668]
332.
Schaafsma JD, Giladi N, Balash Y, et al. Gait dynamics in Parkinson’s disease:relationship to parkinsonian features, falls and response to levodopa. Journal of Neurological Sciences. 2003;212:47–53. Ref ID: 19861. [PubMed: 12809998]
333.
Bloem BR, Grimbergen YA, Cramer M, et al. Prospective assessment of falls in Parkinson’s disease. Journal of Neurology. 2001;248(11):950–958. Ref ID: 19862. [PubMed: 11757958]
334.
Wielinski CL, Erickson-Davis C, Wichmann R, et al. Falls and injuries resulting from falls among patients with Parkinson’s disease and other Parkinsonian syndromes. Early view published online in advance of print. Movement Disorders. 2004;(Dec 3) Ref ID: 19863. [PubMed: 15580552]
335.
National Institute for Health and Clinical Excellence. Falls: The assessment and prevention of falls in older people. Quick reference guide. (Clinical Guideline 21). London: National Institute for Health and Clinical Excellence; 2004. Ref ID: 20126.
336.
Abbott R, Cox M, Markus HS, et al. Diet, body size and micronutrient status in Parkinson’s disease. European Journal of Clinical Nutrition. 1992;46:879–884. Ref ID: 19791. [PubMed: 1483417]
337.
Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson’s disease. Nutrition Reviews. 1994;52:51–58. Ref ID: 19801. [PubMed: 8183469]
338.
Gazewood JD, Mehr R. Diagnosis and Management of weight loss in the elderly. Journal of Family Practice. 1998;47(1):19–25. Ref ID: 19934. [PubMed: 9673603]
339.
Nilsson H, Ekberg O, Olsson R, et al. Quantitative assessment of oral and pharyngeal function in Parkinson’s Disease. Dysphagia. 1996;11(2):144–150. Ref ID: 19923. [PubMed: 8721074]
340.
Logemann JA, Blonsky ER, Boshe SE. Dysphagia in parkisonism. Journal of the American Medical Association. 1975;231(1):69–70. Ref ID: 19924. [PubMed: 1243574]
341.
Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442. Ref ID: 19930. [PubMed: 6067254]
342.
Hunter PC, Crameri J, Austin S, et al. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63:579–583. Ref ID: 19799. [PMC free article: PMC2169826] [PubMed: 9408096]
343.
Sonies BC. Patterns of care for dysphagic patients with degenerative neurological diseases. Seminars in Speech and Language Therapy. 2000;21:4. Ref ID: 19932. [PubMed: 11085257]
344.
Duranceau A. Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia. Neuromuscular Disorders. 1997;(Suppl 1):S85–89. Ref ID: 19931. [PubMed: 9392023]
345.
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurology. 2003;2:107–116. Ref ID: 19802. [PubMed: 12849267]
346.
Ashraf W, Pfeiffer R, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Movement Disorders. 1997;12:946–951. Ref ID: 19793. [PubMed: 9399219]
347.
Gruss HJ, Ulm G. Efficacy and tolerability of PEG 3350 plus electrolytes (Movicol) in chronic constipation associated with Parkinson’s disease. European Journal of Geriatrics. 2004;6:143–150. Ref ID: 19798.
348.
Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. Journal of Neurology, Neurosurgery & Psychiatry. 1997;62:507–511. Ref ID: 19805. [PMC free article: PMC486869] [PubMed: 9153611]
349.
Bronner G, Royter V, Korczyn A, et al. Sexual dysfunction in Parkinson’s disease. Journal of Sex and Marital Therapy. 2004;30:95–105. Ref ID: 19794. [PubMed: 14742099]
350.
Singer C, Weiner WJ, Sanchez-Ramos J. Autonomic dysfunction in men with Parkinson’s disease. European Neurology. 1992;32:134–140. Ref ID: 19804. [PubMed: 1592069]
351.
Allcock LM, Ullyart K, Kenny R, et al. Frequency of orthostatic hypotension in a community acquired cohort of patients with Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2003;75:1470–1471. Ref ID: 19792. [PMC free article: PMC1738761] [PubMed: 15377699]
352.
Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63:584–589. Ref ID: 19803. [PMC free article: PMC2169808] [PubMed: 9408097]
353.
Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clinical Autonomic Research. 1996;6:125–126. Ref ID: 19800. [PubMed: 8726100]
354.
Edwards LL, Pfeiffer R, Quigley E, et al. Gastrointestinal symptoms in Parkinson’s disease. Movement Disorders. 1991;6:151–156. Ref ID: 19796. [PubMed: 2057006]
355.
Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. Journal of Clinical Gastroenterology. 2005;39(2):89–97. Ref ID: 19936. [PubMed: 15681902]
356.
Marks L, Turner K, O’Sullivan J, et al. Drooling in Parkinson’s disease: A novel speech and language therapy Intervention. International Journal of Language and Communication Disorders. 2001;36(Suppl):282–287. Ref ID: 19922. [PubMed: 11340797]
357.
Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Movement Disorders. 2002;17(6):1318. Ref ID: 19935. [PubMed: 12465075]
358.
Sullivan JD, Bhatia KP, Lees AJ. Botulinum toxin A as a treatment for drooling saliva in PD. Neurology. 2000;55:606–607. Ref ID: 19806. [PubMed: 10953215]
359.
Ford B. Pain in Parkinson’s disease. Clinical Neuroscience. 1998;5:63–72. Ref ID: 19897. [PubMed: 10785830]
360.
Parkinson’s Disease Society. Competencies: an integrated career and competency framework for nurses working in PD management. London: Parkinson’s Disease Society; 2005. Ref ID: 19937.
361.
Bell L. Changing roles: the impact of Parkinson’s disease nurse specialists. London: Parkinson’s Disease Society; 2004. Ref ID: 787.
362.
Jarman B, Hurwitz B, Cook A. Effects of community based nurses specialising in Parkinson’s disease on health outcome and costs: randomised controlled trial. British Medical Journal. 2002;324(7345):1072–1075. Ref ID: 223. [PMC free article: PMC104336] [PubMed: 11991913]
363.
Jahanshahi M, Brown RG, Whitehouse C, et al. Contact with a nurse practitioner: A short-term evaluation study in Parkinson’s disease and dystonia. Behavioural Neurology. 1994;7:3–4. 189–196. Ref ID: 200. [PubMed: 24487336]
364.
Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson’s disease nurse specialist. International Journal of Nursing Studies. 2000;37(4):337–349. Ref ID: 744. [PubMed: 10760541]
365.
Hobson P, Roberts S, Meara J. The economic value of a Parkinson’s disease nurse specialist service. Health and Ageing. 2003;3:ii–iii. Ref ID: 19668.
366.
The Chartered Society of Physiotherapy. The Curriculum Framework for qualifying programmes in physiotherapy. London: The Chartered Society of Physiotherapy, The Council for Professions Supplementary to Medicine; 1996. Ref ID: 19660.
367.
Physical therapy management of Parkinson’s disease (clinics in physical therapy). New York: Churchill Livingston; 1992. Ref ID: 19678.
368.
Deane KHO, Jones D, Playford ED, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease.(Cochrane Review). The Cochrane Database of Systematic Reviews. 2001;(3):CD002817. Ref ID: 90. [PubMed: 22895932]
369.
Bergen JL, Toole T, Elliott RG III, et al. Aerobic exercise intervention improves aerobic capacity and movement initiation in Parkinson’s disease patients. NeuroRehabilitation. 2002;17(2):161–168. Ref ID: 2778. [PubMed: 12082243]
370.
Stallibrass C, Sissons P, Chalmers C. Randomized controlled trial of the Alexander technique for idiopathic Parkinson’s disease. Clinical Rehabilitation. 2002;16(7):695–708. Ref ID: 2779. [PubMed: 12428818]
371.
Schenkman M, Cutson TM, Kuchibhatla M, et al. Exercise to improve spinal flexibility and function for people with Parkinson’s disease: a randomized, controlled trial. Journal of the American Geriatrics Society. 1998;46(10):1207–1216. Ref ID: 498. [PubMed: 9777901]
372.
Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson’s disease patients. Movement Disorders. 1996;11(2):193–200. Ref ID: 19573. [PubMed: 8684391]
373.
Hurwitz A. The benefit of a home exercise regimen for ambulatory Parkinson’s disease patients. Journal of Neuroscience Nursing. 1989;21(3):180–184. Ref ID: 415. [PubMed: 2525159]
374.
Patti F, Reggio A, Nicoletti F, et al. Effects of rehabilitation therapy on Parkinson’s disability and functional independence. Journal of Neurologic Rehabilitation. 1996;10(4):223–231. Ref ID: 19572.
375.
World Federation of Occupational Therapists. World federation of Occupational therapists definition 2004. [accessed 20 April 2006 ]. Available from: www​.wfot.com/ Ref ID: 19869.
376.
Birleson A. Occupational therapy in Parkinson’s disease. Geriatric Medicine. 1998;28(1) Ref ID: 19866.
377.
Deane HO, Ellis-Hill C, Dekker K, et al. A survey of current OT practice for Parkinson’s Disease in the UK. British Journal of Occupational Therapy. 2003;66(5):193–200. Ref ID: 19867.
378.
Aragon A. Physical therapies keep your independence with the help of Occupational therapy. The Parkinson. 2004:19–20. Ref ID: 19865.
379.
Deane KHO, Ellis-Hill C, Playford ED, et al. Occupational therapy for Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2001;(2):CD002813. Ref ID: 72. [PubMed: 11687028]
380.
Gauthier L, Dalziel S, Gauthier S. The benefits of group occupational therapy for patients with Parkinson’s disease. The American Journal of Occupational Therapy. 1987;41(6):360–365. Ref ID: 19739. [PubMed: 3688150]
381.
Fiorani CF, Mari F, Bartolini M, et al. Occupational therapy increases ADL score and quality of life in Parkinson’s disease. Movement Disorders. 1997;121:135. Ref ID: 19738.
382.
Erb E. Improving speech in Parkinson’s disease. American Journal of Nursing. 1973;73:1910–1911. Ref ID: 19877. [PubMed: 4490680]
383.
Scott S, Caird FI. Speech Therapy for Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 1983;47:140–144. Ref ID: 19881. [PMC free article: PMC1027296] [PubMed: 6842217]
384.
Robertson SJ, Thomson F. Speech therapy in Parkinson’s disease: a study of the efficacy and long term effects of intensive treatment. British Journal of Disorders of Communication. 1984;19:213–224. Ref ID: 19769. [PubMed: 6508992]
385.
Hanson W, Metter E. DAF speech rate modification in Parkinson’s disease; a report of two cases. In: Berry W, editor. Clinical disarthria. Austin TX: ProEd; 1983. pp. 231–254. Ref ID: 19878.
386.
Rubow R, Swift E. A micro-computer based wearable biofeedback device to improve transfer of treatment in parkinsonian Dysarthria. Journal of Speech and Hearing Disorders. 1985;50:166–178. Ref ID: 19880. [PubMed: 3990263]
387.
Deane KHO, Whurr R, Playford ED, et al. Speech and language therapy versus placebo or no intervention for dysarthria in Parkinson’s disease (Cochrane Review). The Cochrane Database of Systematic Reviews. 2001;(2):CD002812. Ref ID: 77. [PubMed: 11406044]
388.
Johnson JA, Pring TR. Speech Therapy and Parkinson’s disease: A review and further data. British Journal of Disorders of Communication. 1990;25:183–194. Ref ID: 19767. [PubMed: 2206966]
389.
Ramig LO, Sapir S, Fox C, et al. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson’s disease: a comparison with untreated patients and normal age-matched controls. Movement Disorders. 2001;16(1):79–83. Ref ID: 19768. [PubMed: 11215597]
390.
Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up. Journal of Neurology, Neurosurgery & Psychiatry. 2001;71(4):493–498. Ref ID: 19770. [PMC free article: PMC1763504] [PubMed: 11561033]
391.
Baumgartner CA, Sapir S, Ramig TO. Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. Journal of Voice. 2001;15(1):105–114. Ref ID: 20028. [PubMed: 12269625]
392.
Sapir S, Ramig LO, Hoyt P, et al. Speech loudness and quality 12 months after intensive voice treatment (LSVT) for Parkinson’s disease: a comparison with an alternative speech treatment. Folia Phoniatrica et Logopaedica. 2002;54(6):296–303. Ref ID: 20029. [PubMed: 12417800]
393.
Deane KH, Whurr R, Playford ED, et al. Speech and language therapy for dysarthria in Parkinson’s disease. The Cochrane Database of Systematic Reviews. 2001;(2):CD002814. Ref ID: 20030. [PubMed: 11406044]
394.
World Health Organisation. WHO definition of palliative care. [accessed 27 March 2006]. Available from: www​.who.int/cancer/palliative​/definition/en/ Ref ID: 20127.
395.
O’Brien T, Welsh J, Dunn FG. ABC of palliative care. Non-malignant conditions. British Medical Journal. 1998;316(7127):286–289. Ref ID: 19938. [PMC free article: PMC2665479] [PubMed: 9472516]
396.
Scott S, Meadowcroft RS. London: Parkinsons Disease Society; Just invisible: a summary. 2005. Ref ID: 19944.
397.
MacMahon DG, Thomas S. Practical approach to quality of life in Parkinson’s disease: the nurse’s role. Journal of Neurology. 1998;245(Suppl 1):S19–22. Ref ID: 748. [PubMed: 9617718]
398.
MacMahon DG, Thomas S, Campbell S. Validation of pathways paradigm for the management of PD. Parkinsonism & Related Disorders. 1999;5(S53) Ref ID: 19912.
399.
Parkinson’s Disease Society. Carers’ assessment. (FS46). London: Parkinson’s Disease Society; 2003. Ref ID: 19945.
400.
Buchanan S, Willis E. Carers’ guide. London: Parkinson’s Disease Society; 2004. Ref ID: 19946.
401.
Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43:2227–2229. Ref ID: 19914. [PubMed: 8232934]
402.
Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology. 1995;45:669–671. Ref ID: 19913. [PubMed: 7723953]
403.
Mitchell SL, Kiely DK, Kiel DP, et al. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson’s disease. Journal of the American Geriatrics Society. 1996;44(4):394–399. Ref ID: 19915. [PubMed: 8636583]
404.
Thomas S, Macmahon D. Parkinson’s disease, palliative care and older people: Part 2. Nursing Older People. 2004;16(2):22–26. Ref ID: 19692. [PubMed: 15119154]
405.
Thomas S, Macmahon D. Parkinson’s disease, palliative care and older people: Part 1. Nursing Older People. 2004;16(1):22–26. Ref ID: 19693. [PubMed: 15045859]
406.
Thomas S, Macmahon D. Managing Parkinson’s disease in long-term care. Nursing Older People. 2002;14(9):23–30. Ref ID: 20128. [PubMed: 12523041]
407.
National Institute for Health and Clinical Excellence. Pressure relieving devices. London: National Institute for Health and Clinical Excellence; 2003. Ref ID: 19917.
408.
National Institute for Health and Clinical Excellence. Pressure ulcer risk management and prevention (Guideline B). London: National Institute for Health and Clinical Excellence; 2003. Ref ID: 19916.
409.
Royal College of Nursing. Pressure ulcer risk assessment and prevention: implementation guide and audit protocol. Oxford: Royal College of Nursing; 2003. Ref ID: 19918.
410.
Howards A, Pemberton C, Storey L. The preferred place of care plan (PPC). Lancashire: Lancashire and South Cumbria Cancer Network; 2004. Ref ID: 19919.
411.
Macmillan. Gold standards framework. London: Macmillan Cancer Relief; 2005. Cancer Relief. Ref ID: 19920.
412.
Liverpool Care Pathway. Liverpool care pathway for the dying patient. Liverpool: Liverpool Care Pathway; 2005. Ref ID: 19921.
413.
Northumbria University, Katholieke Universiteit, Vrije Universiteit. The rescue project. [accessed on 2 March 2006]. Available from: www​.rescueproject.org​/overview/welcome/html. Ref ID: 20121.
414.
Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. Ref ID: 19448. [PubMed: 11323066]
415.
Thomas S, Macmahon D, Maguire J. Moving and shaping: a guide to commissioning integrated services for people with Parkinson’s disease. 2nd edn. London: Parkinson’s Disease Society; 2006. Ref ID: 41.
416.
Nicholson T, Milne R. Pallidotomy, thalamotomy and deep brain stimulation for severe Parkinson’s disease. Southampton: Wessex Institute for Health Research and Development; 1999. Ref ID: 43.
417.
Bhatia K, Brooks DJ, Burn DJ, et al. Updated guidelines for the management of Parkinson’s disease. Hospital Medicine (London). 2001;62(8):456–470. Ref ID: 9. [PubMed: 11530583]
418.
Curtis L, Netten A. Personal Social Services Research Unit, University of Kent. Canterbury: 2004. Unit costs of health and social care data 2004. Available from: www​.pssru.ac.uk/uc/uc2004.htm.